04:39 AM EDT, 06/16/2025 (MT Newswires) -- Genmab ( GMAB ) said Sunday that results from a phase 1b/2 trial of its experimental epcoritamab treatment in combination with other drugs in patients with relapsed/refractory diffuse large B-cell lymphoma showed an overall response rate of 87%.

The results cover patients who are eligible for autologous stem cell transplantation.

The company said results also showed a complete response rate of 65%, and a partial response rate of 23%.

Safety data from the trial showed a low-grade cytokine release syndrome and no discontinuations due to treatment-emergent adverse events, Genmab ( GMAB ) said.